News
Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of ...
One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback